US Patent

US11026939 — High dosage valbenazine formulation and compositions, methods, and kits related thereto

Method of Use · Assigned to Neurocrine Biosciences Inc · Expires 2038-09-18 · 12y remaining

Vulnerability score 58/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a high dosage formulation of valbenazine tosilate, including specific ingredients and their combinations.

USPTO Abstract

Solid pharmaceutical compositions with high drug loading are provided. A formulation useful for the solid pharmaceutical composition includes valbenazine, or a pharmaceutically acceptable salt thereof, silicified microcrystalline cellulose, isomalt, hydroxypropyl methylcellulose, partially pregelatinized maize starch, and magnesium stearate.

Drugs covered by this patent

valbenazine-tosylate (VALBENAZINE TOSYLATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3055`	—	valbenazine-tosylate
`U-3055`	—	valbenazine-tosylate
`U-3055`	—	valbenazine-tosylate
`U-3055`	—	valbenazine-tosylate
`U-3055`	—	valbenazine-tosylate
`U-1995`	—	valbenazine-tosylate

Patent Metadata

Patent number: US11026939
Jurisdiction: US
Classification: Method of Use
Expires: 2038-09-18
Drug substance claim: No
Drug product claim: Yes
Assignee: Neurocrine Biosciences Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.